Cryoport Inc (CYRX) Stock AnalysisCYRXCryoport Inc

Cryoport, Inc. is a provider of integrated, temperature-controlled supply chain solutions for the life sciences. The Company operates through two segments: segments: Life Sciences Services and Life Sciences Products. Its life sciences services include BioLogistics and BioStorage/BioServices, which provides temperature-controlled logistics, biostorage and bioservices within the life science industry through direct sales. Its life sciences products segment manufactures and sells cryogenic systems, such as freezers and cryogenic dewars and related ancillary accessories used in the storage and transport of life science commodities through direct sales or a distribution network. Its operating units include Cryoport Systems, CryoGene and MVE Biological Solutions (MVE). Cryoport Systems provides temperature-controlled BioLogistics, BioServices, and cryopreservation solutions, supporting clinical and commercial workflows through transport, kit production, labeling, packaging, and others. It operates in the Industrials sector (PHARMACEUTICAL PREPARATIONS industry).

Cryoport Inc (CYRX) appears to be a good buy right now due to its current price of $17.98, which is below the average analyst price target of $19. Additionally, the stock has shown a strong year-to-date change of +88.08% and a recent 5-day change of +6.77%, indicating positive momentum. However, the main risk is its forward P/E ratio of 79.37, suggesting that the stock may be overvalued if earnings do not improve significantly in the near future.

4 analysts cover CYRX: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 11.00.